Levodopa deuterated - Teva Pharmaceutical Industries

Drug Profile

Levodopa deuterated - Teva Pharmaceutical Industries

Alternative Names: Deuterium containing levodopa - Teva Pharmaceutical Industries; Deuterium substituted levodopa - Teva Pharmaceutical Industries; SD-1077

Latest Information Update: 17 Nov 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Imphar AG
  • Developer Teva Pharmaceutical Industries
  • Class Antiparkinsonians; Catecholamines; Organic deuterium compounds; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 05 May 2015 Auspex Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
  • 16 Mar 2015 Auspex Pharmaceuticals has patent protection for levodopa deuterated in USA and European Union (Auspex Pharmaceuticals 10-K, March 2015)
  • 12 Jan 2015 Auspex Pharmaceuticals acquires complete worldwide rights to SD 1077 from Imphar AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top